「小普日報」2023年3月20日熱點速遞

關(guān)鍵詞
基因 禽流感 過敏 腎病 拮抗劑 靶向藥
?
#今日行業(yè)熱點#
①Nature :Humans have lived on the Tibetan Plateau for 5,000 years
DOI :10.1038/d41586-023-00742-6
關(guān)聯(lián)研究:Human genetic history on the Tibetan Plateau in the past 5100 years
DOI :10.1126/sciadv.add5582
②Nature:Bird-flu virus makes itself at home in Canadas foxes and skunks
高致病性禽流感病毒在加拿大的狐貍和臭鼬中橫行
DOI :10.1038/d41586-023-00776-w
③Military Medical Research:Investigation of the cell composition and gene expression in the delayed-type hypersensitivity tuberculin skin tes
遲發(fā)型超敏結(jié)核菌素皮試細(xì)胞組成及基因表達的研究
DOI :10.1186/s40779-023-00450-2
④Science Advances:HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer
HDAC3在Kras-突變的非小細(xì)胞肺癌的腫瘤發(fā)展和耐藥性中的關(guān)鍵作用
DOI :10.1126/sciadv.add3243
⑤Science Immunology:A mast cell-thermoregulatory neuron circuit axis regulates hypothermia in anaphylaxis
肥大細(xì)胞(MCs)通過激活體溫調(diào)節(jié)神經(jīng)回路來促進IgE介導(dǎo)的過敏反應(yīng)
DOI :10.1126/sciimmunol.adc9417
⑥Lancet子刊:Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement
綜述:在接受造血細(xì)胞移植的成人中進行的體外膜氧合的國際聲明
DOI :10.1016/S2213-2600(22)00535-5
⑦口服小分子APOL1抑制劑VX-147用于APOL1介導(dǎo)腎?。ˋMKD)的臨床前與臨床2a期試驗達成主要終點,可有效降低蛋白尿
⑧靶向藥物組合達拉非尼(Dabrafenib,BRAF抑制劑)+曲美替尼(Trametinib,選擇性MEK抑制劑)獲FDA批準(zhǔn)用于低級別膠質(zhì)瘤
⑨IL-17A融合蛋白拮抗劑IMG-020用于中重度化膿性汗腺炎(Hidradenitis Suppurativa, HS)的臨床2b/Ⅲ期研究數(shù)據(jù)在美國皮膚病學(xué)會(AAD)年會發(fā)表
⑩糖基化融合蛋白CAN008(Asunercept)聯(lián)合TMZ/RT(Temozolomide/Radiotherapy)用于I/II 期膠質(zhì)母細(xì)胞瘤試驗長期隨訪數(shù)據(jù)顯示患者五年總體生存率達67%(研究機構(gòu)歷史數(shù)據(jù)僅為8.2%)
科學(xué)探索的世界充滿挑戰(zhàn),AtaGenix致敬每一位拓荒者,更致力于成為您信賴的合作伙伴!